JOINTPROMISE
Jointpromise advocates the development and production of complex joint implants (Joint_ATMP) for the regeneration of joint defects. Novel research results in organoid technologies enable the application of cartilage-like microtissues for 3D bioprinting three-dimensional living joint implants. To meet the demand for regenerative therapies for OA that is rising due to the ageing world population, Jointpromise implements an automated, GMP-grade production platform for the cultivation and handling of microtissues and organoids and their subsequent 3D bioprinting into functional joint implants.
Main objectives
1
Precision automated manufacturing platform
-
Create a robotically-driven, integrated tissue biomanufacturing pipeline able to generate and handle semi-autonomous microtissue modules and the production of complex Joint_ATMPs
-
Create a comprehensive quality control (QC) toolbox, ensuring the quality attributes of Joint_ATMPs from the single cell up to the tissue scale.
2
Safety and efficacy of the manufactured implants
-
Repair of fresh deep osteochondral defects in rats.
-
Repair of large fresh deep osteochondral defects in minipigs: preclinical validation in mini pigs (animal model shown to be closest to the human case)
3
Sustained access for patients and commercial viability for manufacturers
-
Develop and maintain an economic- and landscape roadmap.
-
Account for cost and willingness to pay for the developed tissue engineered product (Joint_ATMP).
Consortium partners:
Project outcomes
Jointpromise is a Horizon 2020 funded project
